Dr. Sven De Vos

Dr. Christos Emmanouilides

Dr. William H. McBride

Dr. Jonathan W. Said

University of Southern California

Jonsson Comprehensive Cancer Center

B-Cell Lymphomas

Grant Amount: $150,000

PHASE ONE sponsored an Indisciplinary Grant to study the use of the Proteasome Inhibitor PS-341 in the treatment of refractory diffuse large B-cell lymphomas in terms of clinical efficacy, mechanisms of resistance and new models of combination therapy. The study was conducted by principal investigator, Sven de Vos, M.D., and co-investigators, Christos Emmanouilides, M.D., William H. McBride, M.D. and Jonathan W. Said, M.D. at the Jonsson Comprehensive Cancer Center.